Deepening the strategic layout of cutting-edge research and development, Jiangxi Bio traveled to Shenzhen for a scientific research visit and exchange.

Published:

2026-10-27


10 month 21 Date to 23 Day, Jiangxi Biology ( 6915.HK Chairman Jing Yue and General Manager Yao Xiaodong led the Group’s research delegation to Shenzhen, where they visited medical research platforms, university R&D institutions, and national-level industrial innovation hubs, with a particular focus on cutting-edge practices in intelligent R&D, the development of research infrastructure, and the commercialization of scientific findings.

Shenzhen is a major hub for cutting-edge biopharmaceutical technologies and innovative resources. 2025 In [year], the city’s biopharmaceutical industry cluster achieved revenues of [amount]. 1,173.56 hundred million yuan; as of 2026 year 7 To date, it has brought together national, provincial, and municipal-level innovation platforms. 200 Home, platform-based service enterprises 13 Home. Leveraging the synergistic advantages of biotechnology and information technology, Shenzhen has… AI In fields such as pharmaceuticals and synthetic biology, an innovation ecosystem has emerged in which cutting-edge research and industrial translation reinforce each other.

For Jiangxi Bio, this fact-finding mission builds on the Group’s existing research and industrial foundations, aiming to draw on cutting-edge expertise, broaden scientific collaborations, and lay the groundwork for a pioneering biopharmaceutical R&D center in Shenzhen as well as an integrated industry‑research‑medical‑application platform. AI The “Smart Laboratory” initiative has accumulated resources, driving the continuous enhancement of polyclonal antibody R&D capabilities.

 

Linking research resources and broadening the horizons of collaborative innovation.

At the first stop of this research visit, the delegation toured the Hetao Shenzhen–Hong Kong Innovation and Technology Cooperation Zone, visiting relevant university laboratories and national-level major research platforms, with a particular focus on laboratory infrastructure, public research services, and… " Medical care, education, research, and industry " Drawing on collaborative experience, we have developed an operational model that integrates interdisciplinary research with specialized technical services, paving the way for future connections with high-quality research resources and opening up new avenues for exploring industry–university–research cooperation.

 

 

Focusing on intelligent R&D, exploring technology transfer and platform collaboration.

During the research visit, the delegation successively toured the Shenzhen Major Scientific Infrastructure for Synthetic Biology and the National Bio‑Manufacturing Industry Innovation Center, with a particular focus on learning… AI With expertise in the application of automation technologies in drug discovery, as well as in the development and operation of platforms for high-throughput screening, process development, and pilot-scale scale-up, we have a deep understanding of the integrated workflow spanning intelligent design, experimental validation, and industrial translation.

This exchange brought to light the perspectives of various stakeholders at each stage of the innovation pipeline, shared key challenges and practical insights from every phase of drug development, and explored how resource sharing and cross‑disciplinary collaboration can streamline the translation pathway from bench to bedside, enabling innovative advances to reach clinical application more efficiently and benefit patients. This has also broadened the Group’s horizons by drawing on the experiences of external platforms and partnering with specialized collaborators, providing valuable guidance for leveraging its own technological expertise in synergy with external strengths to jointly advance pipeline development and the commercialization of research outcomes.

 

 

Visiting innovative pharmaceutical companies to deepen the linkage between technology and health value.

The delegation also visited Shenzhen Hongxin Biotechnology Co., Ltd. to learn about its… RNA Drugs and the body CAR-T R&D progress in these fields, with a focus on mRNA Sequence design and optimization, LNP Engage in exchanges on delivery and cell-targeting technologies, gain insights into their applications in innovative drug development, and broaden the Group’s horizons in antigen‑development and delivery‑technology research.

Subsequently, the delegation visited the Greater Bay Area International Vaccine Innovation Center, jointly established by the Shenzhen Municipal Government and Sanofi Pasteur. Through personal stories and interactive exhibits, the center seamlessly links technological advancement with individual health, highlighting the human value behind scientific research and innovative products, thereby providing valuable guidance for the Group to deepen science communication and enhance public understanding.

 

 

Pooling innovative resources and deepening R&D deployment.

This visit has further broadened the Group’s understanding of cutting-edge technologies, intelligent R&D, and the commercialization of research outcomes, laying a solid foundation for future technology exchanges and collaborative research. Jiangxi Bio will align its own R&D needs with best practices, continuously connect with high‑quality innovation resources, and foster synergy between Shenzhen’s frontier R&D capabilities and the Group’s end-to-end industrial chain. This will support the advancement of polyclonal antibody technologies and the development of an innovative product pipeline, thereby better fulfilling the company’s vision of “providing high‑quality medicines to people around the world.”

Contact us

Add:

Address: No. 198 Huoju Avenue, Jinggangshan Economic & Technological Development Zone, Ji’an, Jiangxi, China

Board Office:

Domestic Sales:

International Sales:

Complaint & Report Hotline:

Pharmacovigilance Hotline:

Company Email:

Investor Relations:

International Sales Email:

Complaint/Report Email:

二维码

WeChat mini-site

二维码

WeChat official account


© Copyright 2025 Jiangxi Institute of Biological Products Inc. | SEO

Business License

Powered by www.300.cn